Susan Moran

3.0k total citations
58 papers, 1.5k citations indexed

About

Susan Moran is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Susan Moran has authored 58 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Molecular Biology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Susan Moran's work include Fibroblast Growth Factor Research (18 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Prostate Cancer Treatment and Research (9 papers). Susan Moran is often cited by papers focused on Fibroblast Growth Factor Research (18 papers), Radiopharmaceutical Chemistry and Applications (12 papers) and Prostate Cancer Treatment and Research (9 papers). Susan Moran collaborates with scholars based in United States, Germany and Spain. Susan Moran's co-authors include Nancy A. Rigotti, Henry Wechsler, Jon F. Merz, Pamela Sankar, Nora L. Jones, Stephen Lake, Ann Bass, Krzysztof Selmaj, Suzanne Gazda and Edward Fox and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Neurology.

In The Last Decade

Susan Moran

57 papers receiving 1.4k citations

Peers

Countries citing papers authored by Susan Moran

Since Specialization

Citations

This map shows the geographic impact of Susan Moran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Moran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Moran more than expected).

Fields of papers citing papers by Susan Moran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Moran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Moran. The network helps show where Susan Moran may publish in the future.

Co-authorship network of co-authors of Susan Moran

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Moran. A scholar is included among the top collaborators of Susan Moran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Moran. Susan Moran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry 2025 ·Journal of Nuclear Medicine ·Clément Morgat, Heying Duan, Simone U. Dalm, Elif Hindié, (unknown), Bernd J. Krause, Vasko Kramer, Florine Cavelier, Andrew Stephens, Susan Moran, Laura E. Lamb, Andrei Iagaru	2
2	Abstract 2585: First in human study with a novel peptide binder to glypican-3, demonstrates high specificity as a PET imaging agent in patients with hepatocellular carcinoma 2024 ·Cancer Research ·(unknown), Sanjana Ballal, (unknown), (unknown), Ye Yuan, (unknown), (unknown), (unknown), Susan Moran, (unknown), (unknown)	1
3	Abstract 5042: Anti-tumor activity of RYZ101 (Ac-225 DOTATATE) in somatostatin receptor-expressing preclinical models of small-cell lung cancer 2023 ·Cancer Research ·Guangzhou Han, Eunmi Hwang, Fanching Lin, (unknown), Daniel Kim, Eric D. Bischoff, Susan Moran, Gary Li	1
4	ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA 2023 ·Endocrine Abstracts ·Thomas A. Hope, Samuel A. Mehr, Michael J. Morris, Daneng Li, (unknown), Jonathan Strosberg, Heloisa P. Soares, Heather A. Jacene, Marianne Pavel, (unknown), (unknown), Joanne Li, (unknown), (unknown), Susan Moran, Simron Singh	1
5	Where Are All the Women in Industry Advisory Boards? 2022 ·Journal of Clinical Oncology ·Rachna T. Shroff, Karyn A. Goodman, Janice M. Mehnert, Julie M. Vose, Susan Moran, (unknown), Lance Baldo, Brian M. Alexander, (unknown), (unknown), Pamela L. Kunz	6
6	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma 2021 ·Clinical Genitourinary Cancer ·Yung Lyou, Jonathan E. Rosenberg, Jean Hoffman‐Censits, David I. Quinn, Daniel P. Petrylak, Matthew D. Galsky, Ulka N. Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A. Burris, (unknown), Li Ai, (unknown), Corina Andresen, Susan Moran, Siamak Daneshmand, Dean F. Bajorin, Sumanta K. Pal, Petros Grivas	10
7	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma 2020 ·European Urology ·Yung Lyou, Petros Grivas, Jonathan E. Rosenberg, Jean Hoffman‐Censits, David I. Quinn, Daniel P. Petrylak, Matthew D. Galsky, Ulka N. Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A. Burris, (unknown), (unknown), Hao Wang, (unknown), Susan Moran, Siamak Daneshmand, Dean F. Bajorin, Sumanta K. Pal	21
8	Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor 2020 ·Ophthalmology ·M. Teresa Magone, Iris R. Hartley, Edmond J. FitzGibbon, Rachel Bishop, (unknown), Susan Moran, (unknown), Jaydira Del Rivero, (unknown), (unknown), Kelly L. Roszko, Michael T. Collins, Rachel I. Gafni	10
9	Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial 2019 ·Annals of Oncology ·Milind Javle, Ivan Borbath, Stephen Clarke, Erika Hitre, Christophe Louvet, Teresa Macarulla, Do‐Youn Oh, Jennifer L. Spratlin, Juan Carlos del Valle, Karl Heinz Weiss, (unknown), Michael F. Howland, (unknown), (unknown), Susan Moran, Ghassan K. Abou‐Alfa	4
10	The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea 2019 ·Breast Cancer Research and Treatment ·Hope S. Rugo, Jack A. Di Palma, Debu Tripathy, Richard Bryce, Susan Moran, Elizabeth Olek, Linda D. Bosserman	50
11	Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model 2018 ·Cancer Chemotherapy and Pharmacology ·Kate R. Secombe, (unknown), (unknown), Anthony Wignall, John Finnie, Dorothy Keefe, Francesca Avogadri-Connors, Elizabeth Olek, (unknown), Susan Moran, Joanne M. Bowen	11
12	Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions 2018 ·Annals of Oncology ·Milind Javle, Robin Kate Kelley, Sameek Roychowdhury, K.H. Weiss, Ghassan K. Abou‐Alfa, Teresa Macarulla, Saeed Sadeghi, Dirk Waldschmidt, Andrew X. Zhu, Lipika Goyal, Mitesh J. Borad, Wei Peng Yong, Ivan Borbath, Anthony B. El-Khoueiry, P. A. Philip, Susan Moran, (unknown), (unknown), Nancy Lewis, Tanios Bekaii‐Saab	33
13	Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial 2017 ·Annals of Oncology ·Suzette Delaloge, (unknown), David Cella, Marc Buyse, Arlene Chan, Carlos H. Barrios, Frankie A. Holmes, Janine Mansi, Hiroji Iwata, Bent Ejlertsen, Beverly Moy, Gϋnter von Minckwitz, Stephen Chia, Michael Gnant, Snezhana Smichkoska, (unknown), Susan Moran, Alan Auerbach, Lesley Fallowfield, M. Martín Jiménez	2
14	Effective Management and Prevention of Neratinib-Induced Diarrhea 2015 ·(unknown), Cristina Saura, (unknown), Richard Bryce, Susan Moran, (unknown), (unknown)	16
15	Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer 2015 ·Investigational New Drugs ·Daniel P. Petrylak, (unknown), William R. Clark, Elisabeth I. Heath, Jianqing Lin, William Oh, David B. Agus, Bradley Curtis Carthon, Susan Moran, Ning Kong, Ajit Suri, (unknown), Glenn Liu	12
16	Patient perspectives on medical confidentiality 2003 ·Journal of General Internal Medicine ·Pamela Sankar, Susan Moran, Jon F. Merz, Nora L. Jones	88
17	Students’ opinion of tobacco control policies recommended for US colleges: a national survey 2003 ·Tobacco Control ·Nancy A. Rigotti, (unknown), Susan Moran, Henry Wechsler	63
18	Physicians' missed opportunities to address tobacco use during prenatal care 2003 ·Nicotine & Tobacco Research ·Susan Moran, Anne N. Thorndike, Katrina Armstrong, Nancy A. Rigotti	26
19	First Clinical Evaluation of Ganstigmine in Patients With Probable Alzheimer's Disease 2003 ·Clinical Neuropharmacology ·Stanford S. Jhee, Laura Fabbri, (unknown), (unknown), Susan Moran, Victoria Zarotsky, (unknown), Edyta J. Frackiewicz, Thomas Shiovitz	6
20	[Dietetic manipulations in patients with hepatic encephalopathy]. 1994 ·PubMed ·Misael Uribe, Susan Moran, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact